# Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors

> **NCT06014658** · PHASE1,PHASE2 · RECRUITING · sponsor: **MBrace Therapeutics** · enrollment: 130 (estimated)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Antibody-Drug Conjugate

## Key facts

- **NCT ID:** NCT06014658
- **Lead sponsor:** MBrace Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-07
- **Primary completion:** 2026-07
- **Final completion:** 2026-11
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06014658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06014658, "Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors". Retrieved via AI Analytics 2026-07-14 from https://api.ai-analytics.org/clinical/NCT06014658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*